Upsher-Smith launches generic Lomotil
Upsher-Smith Laboratories has launched diphenoxylate hydrochloride and atropine sulfate tablets 2.5 mg/0.025 mg.
Upsher-Smith's product is the generic version of Pfizer’s Lomotil (diphenoxylate hydrochloride and atropine sulfate) tablets. Lomotil is indicated as adjunctive therapy in the management of diarrhea in patients 13 years old and older.
Diphenoxylate hydrochloride and atropine sulfate tablets had a market value of approximately $64 million for the 12 months ended May, 2018, according to IQVIA.
Upsher-Smith's product is the generic version of Pfizer’s Lomotil (diphenoxylate hydrochloride and atropine sulfate) tablets. Lomotil is indicated as adjunctive therapy in the management of diarrhea in patients 13 years old and older.
Diphenoxylate hydrochloride and atropine sulfate tablets had a market value of approximately $64 million for the 12 months ended May, 2018, according to IQVIA.